Capital International Ltd. CA Invests $2.64 Million in Ascendis Pharma A/S (NASDAQ:ASND)

Capital International Ltd. CA purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 19,153 shares of the biotechnology company's stock, valued at approximately $2,637,000.

Other institutional investors also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB acquired a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth about $30,000. Jones Financial Companies Lllp lifted its position in shares of Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after buying an additional 197 shares during the last quarter. Blue Trust Inc. boosted its holdings in shares of Ascendis Pharma A/S by 415.2% in the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after buying an additional 328 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after buying an additional 214 shares during the last quarter. Finally, Sanctuary Advisors LLC acquired a new stake in Ascendis Pharma A/S during the 4th quarter worth $203,000.

Ascendis Pharma A/S Price Performance

NASDAQ:ASND traded down $2.08 during trading hours on Thursday, reaching $156.06. 143,673 shares of the company traded hands, compared to its average volume of 485,905. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $169.37. The stock has a market cap of $9.52 billion, a P/E ratio of -21.98 and a beta of 0.54. The firm's 50-day moving average is $153.31 and its 200-day moving average is $138.53.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($1.32) by $0.64. As a group, research analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Morgan Stanley set a $180.00 target price on Ascendis Pharma A/S in a report on Tuesday, February 18th. Cantor Fitzgerald lifted their target price on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a report on Tuesday, February 25th. The Goldman Sachs Group raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. lifted their price objective on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an "overweight" rating in a research note on Tuesday, March 18th. Finally, Evercore ISI increased their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 18th. Two research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $204.67.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.